Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression
A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety…